Laurence Nore

Laurence Nore has a wealth of experience in the biopharmaceutical industry. Laurence began their career in 2006 as Associate Director of Commercial Development and New Product Planning at PDL BioPharma. In this role, they managed complex partnerships and recommended significant changes to the MS program. From 2008 to 2009, they were Director of Business and Commercial Development at Perlegen Sciences, where they developed the investment rationale for a Series E round and drove the company's pivot from discovery to pre-commercial. Laurence then moved to Ventana Medical Systems as Director of Business Development, where they closed a $100M acquisition and established a partnership with a leader in spectral imaging technology. From 2011 to 2015, they were Lead of Biomarkers and Companion Diagnostics at EMD Millipore, where they led a cross-functional team and supervised the filing of a pre-IND briefing document. From 2017 to 2021, they were VP of Commercial and Business Development at Medicines360, where they focused on transforming and uniquely positioning the company within the Women’s Health ecosystem. Most recently, they have served as CBO Advisor at Metanoia Bio Inc, US Business Advisor at INATHERYS, and Business Development Advisor at Nammi Therapeutics, Inc. Laurence is currently the EVP of Business Development and Operations at IgGenix, Inc.

Laurence Nore obtained an MBA from UCLA Anderson School of Management between 1999 and 2001, with a focus on Finance, Strategy, and Marketing. Laurence also earned a Bachelor of Arts (B.A.) from emlyon business school between 1986 and 1989, with a focus on Business Administration and Management, General.